Stockscreener 앱 받기
0.7975
4.06%
0.0311
시간 외 거래:
.82
0.0225
+2.82%
Femasys Inc 주식(FEMY)의 최신 뉴스
Femasys Inc. Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - marketscreener.com
FDA clears FemVue Controlled for in-office tubal assessment - Contemporary OB/GYN
Femasys secures U.S. FDA clearance for next-generation Femvue diagnostic device - marketscreener.com
Femasys Gains FDA Clearance for FemVue Diagnostic Device - TipRanks
Femasys Inc Secures FDA Clearance for FemVue Diagnostic Device - TradingView — Track All Markets
Femasys receives FDA clearance for FemVue Controlled diagnostic device - Investing.com
Femasys Inc. Receives FDA Clearance for Innovative FemVue Controlled Device to Enhance Fallopian Tube Evaluation and Workflow Efficiency - Quiver Quantitative
New device could make fallopian tube testing simpler for fertility care - Stock Titan
Femasys Secures Major Order for FemBloc Launch - MSN
Femasys Receives FDA Approval for FemBloc Trial - MSN
FDA Approves Final Trial Phase for Femasys’ Permanent Birth Control Product - Medical Product Outsourcing
PharmaCyte’s Successful Stake Earns them Millions - StocksToTrade
PharmaCyte Boosts Financial Position with Femasys Stake Sale - timothysykes.com
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
Femasys Inc Stock Analysis and ForecastTechnical Breakout Signals & Minimal Capital Trading - earlytimes.in
CapEx per share of Femasys Inc. – NASDAQ:FEMY - TradingView
Femasys (NASDAQ:FEMY) Rating Increased to Hold at Wall Street Zen - MarketBeat
PharmaCyte Biotech stock surges following profitable exit from Femasys investment - MSN
Why Femasys Inc. stock is a must watch in 20252025 Earnings Impact & High Return Trade Guides - BỘ NỘI VỤ
PharmaCyte Biotech sells Femasys stake, boosts cash position to $20 million - Investing.com Nigeria
PharmaCyte Biotech stock soars after successful Femasys stake sale By Investing.com - Investing.com Australia
PharmaCyte Biotech stock soars after successful Femasys stake sale - Investing.com India
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Lelezard
PharmaCyte Biotech sells Femasys stake, boosts cash position to $20 million By Investing.com - Investing.com South Africa
PharmaCyte Biotech (Nasdaq: PMCB) Now Holds ~$20M Cash, $25M in Marketable Securities - Stock Titan
Femasys Inc. (FEMY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Femasys (FEMY) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Laidlaw initiates Femasys stock with Buy rating on FemaSeed potential By Investing.com - Investing.com South Africa
Femasys initiated with a Buy at Laidlaw - TipRanks
Why retail investors pile into Femasys Inc. stockJuly 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Is Femasys Inc. stock oversold or undervaluedJuly 2025 PreEarnings & Real-Time Volume Trigger Notifications - newser.com
Laidlaw initiates Femasys stock with Buy rating on FemaSeed potential - Investing.com
Is Femasys Inc. stock attractive for growth ETFsEarnings Summary Report & Safe Capital Growth Stock Tips - newser.com
What margin trends mean for Femasys Inc. stockRate Hike & Fast Exit Strategy with Risk Control - newser.com
Is Femasys Inc. stock affected by interest rate hikesInsider Buying & Verified Entry Point Detection - newser.com
[Form 4] FEMASYS INC Insider Trading Activity - Stock Titan
1.14%
0.54%
자본화:
|
볼륨(24시간):